Skip to Content

New treatment option for refractory metastatic colorectal cancer – trifluridine/tipiracil plus bevacizumab

In the global phase 3 SUNLIGHT study, presented at the 2023 ASCO GI, results showed that combining trifluridine/tipiracil with bevacizumab can significantly increase overall survival in patients with metastatic colorectal cancer who have been heavily pretreated. Josep Tabernero, Professor and Director of the Vall d’Hebron Institute of Oncology, Barcelona, presents the findings of the study in this MEDtalk.

Josep Tabernero

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top